Business Standard

Jubilant to double injectable capacity in US at a cost of $193 mn

Signs agreement with US biomedical dept

Pharma stocks, firms, earnings
Premium

Sohini Das Mumbai
Indian pharma firm Jubilant Pharmova (earlier Jubilant Lifesciences) will now aid the US to expand its critical vaccine manufacturing capacity. The company, a pharmaceutical contract research and manufacturing firm, has entered an agreement with the Army Contracting Command, US through its subsidiary Jubilant HollisterStier LLC to expand critical vaccine manufacturing capacity.

“The effort was funded under the American Rescue Plan; this agreement will enable the company to double its injectable filling production capacity at a total cost of $193 million, at its Spokane, Washington manufacturing facility. This will be completed by 2025,” Jubilant said. This agreement is in addition to

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 30 2022 | 6:43 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com